Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...

(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the ...

As per the agreement, CSL will hand over $355m upfront and up to $1.2bn in potential commercial milestone payments to join Alentis in its efforts to develop and commercialise the novel drug across ...

Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...

Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.

On Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to ...

Travere Therapeutics ( ) has issued an announcement. On September 21, 2026, Travere Therapeutics announced that President and Chief Executive Officer Eric Dube, Ph.D., will step d ...

Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary Leadership SAN DIEGO-- (BUSINESS WIRE)-- $TVTX --Travere Therapeutics ...

Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With the stock now reflecting ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...